{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:38:38Z","timestamp":1791412718006,"version":"4.3.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00259-019-04420-6","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T08:04:21Z","timestamp":1562573061000},"page":"2760-2769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma"],"prefix":"10.1007","volume":"46","author":[{"given":"Marius E.","family":"Mayerhoefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Tal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schilksy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"4420_CR1","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/annonc\/mds643","volume":"24","author":"M Dreyling","year":"2013","unstructured":"Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, et al. ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857\u201377.","journal-title":"Ann Oncol"},{"key":"4420_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558\u201365.","journal-title":"Blood"},{"issue":"2","key":"4420_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2967\/jnumed.118.210047","volume":"60","author":"Jasmin Mettler","year":"2018","unstructured":"Mettler J, M\u00fcller H, Voltin CA, Baues C, Klaeser B, Moccia A, et al. Metabolic tumour volume for response prediction in advanced-stage Hodgkin lymphoma. J Nucl Med. 2019;60:207\u201311. \nhttps:\/\/doi.org\/10.2967\/jnumed.118.210047\n\n.","journal-title":"Journal of Nuclear Medicine"},{"key":"4420_CR4","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34:3618\u201326.","journal-title":"J Clin Oncol"},{"key":"4420_CR5","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, Phillips M, M\u00f8ller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4420_CR6","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","volume":"126","author":"L Ceriani","year":"2015","unstructured":"Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, et al. Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126:950\u20136.","journal-title":"Blood"},{"key":"4420_CR7","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","volume":"22","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, et al. Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma. Clin Cancer Res. 2016;22:3801\u20139.","journal-title":"Clin Cancer Res"},{"key":"4420_CR8","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1007\/s00259-017-3776-3","volume":"44","author":"S Becker","year":"2017","unstructured":"Becker S, Vermeulin T, Cottereau AS, Boissel N, Vera P, Lepretre S. Predictive value of (18)F-FDG PET\/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial. Eur J Nucl Med Mol Imaging. 2017;44:2034\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4420_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2967\/jnumed.117.193946","volume":"59","author":"AS Cottereau","year":"2018","unstructured":"Cottereau AS, El-Galaly TC, Becker S, Broussais F, Petersen LJ, Bonnet C, et al. Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients. J Nucl Med. 2018;59:589\u201395.","journal-title":"J Nucl Med"},{"key":"4420_CR10","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/MNM.0b013e32832e0c13","volume":"30","author":"M Karam","year":"2009","unstructured":"Karam M, Ata A, Irish K, Feustel PJ, Mottaghy FM, Stroobants SG, et al. FDG positron emission tomography\/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome. Nucl Med Commun. 2009;30:770\u20138.","journal-title":"Nucl Med Commun"},{"issue":"7","key":"4420_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s12149-019-01354-9","volume":"33","author":"Domenico Albano","year":"2019","unstructured":"Albano D, Bosio G, Bianchetti N, Pagani C, Re A, Tucci A, et al. Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in mantle cell lymphoma. Ann Nucl Med. 2019. \nhttps:\/\/doi.org\/10.1007\/s12149-019-01354-9\n\n.","journal-title":"Annals of Nuclear Medicine"},{"key":"4420_CR12","doi-asserted-by":"publisher","first-page":"R150","DOI":"10.1088\/0031-9155\/61\/13\/R150","volume":"61","author":"SS Yip","year":"2016","unstructured":"Yip SS, Aerts HJ. Applications and limitations of radiomics. Phys Med Biol. 2016;61:R150\u201366.","journal-title":"Phys Med Biol"},{"key":"4420_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s00259-018-4138-5","volume":"46","author":"SH Moon","year":"2019","unstructured":"Moon SH, Kim J, Joung JG, Cha H, Park WY, Ahn JS, et al. Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. Eur J Nucl Med Mol Imaging. 2019;46:446\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4420_CR14","doi-asserted-by":"crossref","first-page":"67302","DOI":"10.18632\/oncotarget.11693","volume":"7","author":"ER Choi","year":"2016","unstructured":"Choi ER, Lee HY, Jeong JY, Choi YL, Kim J, Bae J, et al. Quantitative image variables reflect the intratumoral pathologic heterogeneity of lung adenocarcinoma. Oncotarget. 2016;7:67302\u201313.","journal-title":"Oncotarget"},{"key":"4420_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature12625","volume":"501","author":"RA Burrell","year":"2013","unstructured":"Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501:338\u201345.","journal-title":"Nature"},{"key":"4420_CR16","doi-asserted-by":"crossref","first-page":"10051","DOI":"10.18632\/oncotarget.7067","volume":"7","author":"LG Morris","year":"2016","unstructured":"Morris LG, Riaz N, Desrichard A, \u015eenbabao\u011flu Y, Hakimi AA, Makarov V, et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget. 2016;7:10051\u201363.","journal-title":"Oncotarget"},{"key":"4420_CR17","doi-asserted-by":"publisher","first-page":"e416","DOI":"10.1038\/emm.2017.165","volume":"50","author":"J Liu","year":"2018","unstructured":"Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer. Exp Mol Med. 2018;50:e416.","journal-title":"Exp Mol Med"},{"key":"4420_CR18","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","volume":"1","author":"R Sun","year":"2018","unstructured":"Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;1:1180\u201391.","journal-title":"Lancet Oncol"},{"key":"4420_CR19","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.1158\/1078-0432.CCR-17-3783","volume":"24","author":"H Park","year":"2018","unstructured":"Park H, Lim Y, Ko ES, Cho HH, Lee JE, Han BK, et al. Radiomics signature on magnetic resonance imaging: association with disease-free survival in patients with invasive breast cancer. Clin Cancer Res. 2018;24:4705\u201314.","journal-title":"Clin Cancer Res"},{"key":"4420_CR20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00259-018-4139-4","volume":"46","author":"MA Arshad","year":"2019","unstructured":"Arshad MA, Thornton A, Lu H, Tam H, Wallitt K, Rodgers N, et al. Discovery of pre-therapy 2-deoxy-2-(18)F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2019;46:455\u201366.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"4420_CR21","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1158\/1078-0432.CCR-18-2861","volume":"25","author":"Sungwon Kim","year":"2019","unstructured":"Kim S, Shin J, Kim DY, Choi GH, Kim MJ, Choi JY. Radiomics on gadoxetic acid-enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single hepatocellular carcinoma. Clin Cancer Res. 2019. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2861\n\n.","journal-title":"Clinical Cancer Research"},{"key":"4420_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140830","volume":"10","author":"S Kanoun","year":"2015","unstructured":"Kanoun S, Tal I, Berriolo-Riedinger A, Rossi C, Riedinger JM, Vrigneaud JM, et al. Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in Hodgkin lymphoma. PLoS One. 2015;10:e0140830.","journal-title":"PLoS One"},{"key":"4420_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181\u2013200.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4420_CR24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1109\/TSMC.1973.4309314","volume":"3","author":"R Haralick","year":"1973","unstructured":"Haralick R, Shanmugan K, Dinstein I. Textural features for image classification. IEEE Trans Syst Man Cybernet. 1973;3:610\u201321.","journal-title":"IEEE Trans Syst Man Cybernet"},{"key":"4420_CR25","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2967\/jnumed.117.199935","volume":"59","author":"F Orlhac","year":"2018","unstructured":"Orlhac F, Boughdad S, Philippe C, Stalla-Bourdillon H, Nioche C, Champion L, et al. A postreconstruction harmonization method for multicenter radiomic studies in PET. J Nucl Med. 2018;59:1321\u20138.","journal-title":"J Nucl Med"},{"key":"4420_CR26","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","volume":"130","author":"AJ Moskowitz","year":"2017","unstructured":"Moskowitz AJ, Sch\u00f6der H, Gavane S, Thoren KL, Fleisher M, Yahalom J, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017;130:2196\u2013203.","journal-title":"Blood"},{"key":"4420_CR27","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"4420_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature14539","volume":"521","author":"Y LeCun","year":"2015","unstructured":"LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521:436\u201344.","journal-title":"Nature"},{"key":"4420_CR29","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132:1647\u201356.","journal-title":"Blood"},{"key":"4420_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.oraloncology.2018.01.030","volume":"78","author":"NM Cheng","year":"2018","unstructured":"Cheng NM, Fang YD, Tsan DL, Lee LY, Chang JT, Wang HM, et al. Heterogeneity and irregularity of pretreatment (18)F-fluorodeoxyglucose positron emission tomography improved prognostic stratification of p16-negative high-risk squamous cell carcinoma of the oropharynx. Oral Oncol. 2018;78:156\u201362.","journal-title":"Oral Oncol"},{"key":"4420_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189766","volume":"13","author":"S Park","year":"2018","unstructured":"Park S, Ha S, Lee SH, Paeng JC, Keam B, Kim TM, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS One. 2018;13:e0189766.","journal-title":"PLoS One"},{"key":"4420_CR32","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s00259-018-4100-6","volume":"45","author":"EJ van Helden","year":"2018","unstructured":"van Helden EJ, Vacher YJL, van Wieringen WN, van Velden FHP, Verheul HMW, Hoekstra OS, et al. Radiomics analysis of pre-treatment [(18)F]FDG PET\/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment. Eur J Nucl Med Mol Imaging. 2018;45:2307\u201317.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4420_CR33","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1186\/s12885-018-4432-4","volume":"18","author":"JMM Rogasch","year":"2018","unstructured":"Rogasch JMM, Hundsdoerfer P, Hofheinz F, Wedel F, Schatka I, Amthauer H, et al. Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma. BMC Cancer. 2018;18:521.","journal-title":"BMC Cancer"},{"key":"4420_CR34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s12149-018-1260-1","volume":"32","author":"A Parvez","year":"2018","unstructured":"Parvez A, Tau N, Hussey D, Maganti M, Metser U. (18)F-FDG PET\/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival. Ann Nucl Med. 2018;32:410\u20136.","journal-title":"Ann Nucl Med"},{"key":"4420_CR35","doi-asserted-by":"publisher","first-page":"18250","DOI":"10.1073\/pnas.1314608110","volume":"110","author":"S Be\u00e0","year":"2013","unstructured":"Be\u00e0 S, Vald\u00e9s-Mas R, Navarro A, Salaverria I, Mart\u00edn-Garcia D, Jares P, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2013;110:18250\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"4420_CR36","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1200\/JCO.2018.77.9124","volume":"36","author":"Qian Shi","year":"2018","unstructured":"Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, Pfreundschuh M, et al. Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). J Clin Oncol. 2018;36:2593\u2013602.","journal-title":"Journal of Clinical Oncology"},{"key":"4420_CR37","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1038\/s41467-018-04316-3","volume":"9","author":"DC Mocanu","year":"2018","unstructured":"Mocanu DC, Mocanu E, Stone P, Nguyen PH, Gibescu M, Liotta A. Scalable training of artificial neural networks with adaptive sparse connectivity inspired by network science. Nat Commun. 2018;9:2383.","journal-title":"Nat Commun"},{"key":"4420_CR38","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1109\/TNB.2015.2461219","volume":"14","author":"G Ditzler","year":"2015","unstructured":"Ditzler G, Polikar R, Rosen G. Multi-layer and recursive neural networks for metagenomic classification. IEEE Trans Nanobiosci. 2015;14:608\u201316.","journal-title":"IEEE Trans Nanobiosci"},{"key":"4420_CR39","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s13244-018-0639-9","volume":"9","author":"R Yamashita","year":"2018","unstructured":"Yamashita R, Nishio M, Do RKG, Togashi K. Convolutional neural networks: an overview and application in radiology. Insights Imaging. 2018;9:611\u201329.","journal-title":"Insights Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04420-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04420-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04420-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T23:16:19Z","timestamp":1594077379000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04420-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":39,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4420"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04420-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,8]]},"assertion":[{"value":"19 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.E.M. has received speaker honoraria and research support from Siemens Healthineers, and speaker honoraria from Bristol-Myers Squibb. H.S. has received honoraria for consultancy from Aileron Therapeutics. All other authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (IRB) and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived by the IRB due to the retrospective design.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}